To assess the seriousness in COVID-19 patients with the blood test report.

Completed

• Conditions: Coronavirus as the cause of diseases classified elsewhere, (2) ICD-10 Condition: B349||Viral infection, unspecified,

• Registration Number: CTRI/2020/07/026574
• Lead Sponsor: AIIMS Hospital

Brief Summary

Of note, a high incidence of lymphopenia in COVID-19 patients has been seen. In addition, the baseline neutrophil-to-lymphocyte ratio (NLR) has been confirmed as a potential prognostic indicator for patients in various other studies. So identifying severe patients in the early stage is of great significance for reducing the clinical morbidity and improving the cure rate. So, we aimed to compare peripheral blood neutrophil to lymphocyte count ratio (NLR) and platelet to lymphocyte ratio to explore the clinical indicator that can predict severity of COVID-19 in the early stage.

Patients clinical symptoms and signs will be obtained from electronic medical records or files when the patient is  admitted and receiving the treatment. All the relevant routine laboratory investigations will be noted from the electronic data records at the time of receiving the treatment. If required  follow-up on telephone consultation will be done on the discharge.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-07-20
• Last Update Posted: 2023-06-07

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Only confirmed cases of COVID-19 diagnosed on the basis of ICMR standard.

Exclusion Criteria

• 1.Age below 6 years.
• 2.Pregnant patients 3.Dialysis dependent patients 4.All trauma patients 5.Any malignancy 6.Any psychiatric illness 7.Consent not given.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To evaluate the ability of the NLR and PLR to predict severity in COVID-19 patients.	Baseline-on admission

Secondary Outcome Measures

Name	Time	Method
1. Mortality	2. Length of hospitalization

Trial Locations

Locations (1)

COVID Centre,AIIMS, New Delhi; 🇮🇳 South, DELHI, India

COVID Centre,AIIMS, New Delhi

🇮🇳South, DELHI, India

Yudhyavi Singh

Principal investigator

9811140057

yudhyavir@gmail.com